Please assess the completion status of the following clinical trial:

Trial Title: A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Informed consent obtained prior to any study-mandated procedure,~* Males aged from 18 to 85 and postmenopausal females aged up to 85 years,~* Onset of symptoms of AMI of more than 30 min and less than 6 hours prior to randomization,~* Subjects presenting a type I AMI including STEMI or NSTEMI.~Main Exclusion Criteria:~* Cardiogenic shock or severe hemodynamic instability,~* Cardiopulmonary resuscitation,~* Loading dose of any oral P2Y12 receptor antagonist prior to randomization,~* Planned fibrinolytic therapy or any fibrinolytic therapy administered within 24 h prior to randomization,~* Known platelet disorders (e.g., thromboasthenia, thrombocytopenia, von Willebrand disease).~* Active internal bleeding, or bleeding diathesis or conditions associated with high risk of bleeding.~* Known clinically important anemia.~* Oral anticoagulation therapy within 7 days prior to randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Selatogrel 8 mg (Type: EXPERIMENTAL): Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.
- Selatogrel 16 mg (Type: EXPERIMENTAL): Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.

Based on this trial design, predict the completion outcome and termination type (if applicable).